CYBB and Stroke: Since then, this paradigm has been tested in numerous models using small molecules and Nox1-, Nox2-, and Nox4-deficient mice, resulting in different outcomes and leading to disputes whether Nox2 [26] or Nox4 [7] isoform is the key pharmacological target for stroke [24].